Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1205 vs Lucentis in wet AMD
CTR20191290Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1205 in exudative macular degeneration, sponsored by Qilu Pharmaceutical. Started Jul 2019; status: completed.
02
Drugs
QL1205
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20191290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191290.